Virax Biolabs Locks In Exclusive Fosun Diagnostics Supply Deal Across Six Southeast Asian Markets
VRAX has more than doubled off its 52-week low of $2.5.
Summary
Virax Biolabs signed an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect product line, covering six Southeast Asian markets and enabling immediate commercial sales. The deal provides a near-term revenue stream and regional validation for the micro-cap biotech, which recently disclosed a going-concern warning.
Key Events · M&A and Partnerships · VRAX
-
Exclusive Supply Deal with Fosun Diagnostics
Through its UK subsidiary, Virax entered an exclusive commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling product line across six Southeast Asian markets: Thailand, Vietnam, Indonesia, Philippines, Singapore, and Malaysia.
-
Immediate Revenue Opportunity
The agreement establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue. Initial focus is tuberculosis-related research applications in Thailand, with rollout potential across the region.
-
Scalable Commercial Framework
Structured volume-based pricing tiers are built into the deal, along with a pathway for phased expansion into additional products, higher-volume supply arrangements, and potential OEM or private-label opportunities.
-
Strategic Partner Validation
Fosun Diagnostics is part of Fosun Pharma, a global healthcare group with 2025 revenue of RMB41.662 billion (~US$5.8 billion), providing Virax with an established commercial infrastructure and customer network in the ASEAN region.
Analysis · VRAX · Life Sciences
A micro-cap biotech carrying a going-concern warning and minimal revenue, Virax Biolabs has landed an exclusive commercial supply agreement with Fosun Diagnostics, a subsidiary of the $5.8B Fosun Pharma. Covering six Southeast Asian markets for its ImmuneSelect immune profiling product line, the deal enables immediate purchase-order-driven supply. That creates a near-term revenue opportunity and validates the technology through a major regional partner, directly addressing the company's cash runway concerns. The agreement also lays out a framework for expansion into higher-volume and OEM arrangements, offering a scalable commercial path separate from its clinical-stage ViraxImmune platform.
At the time of this filing, VRAX was trading at $5.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $2.50 to $28.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.